![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Monday, April 25, 2005 2:15:59 PM
just now are in the process of enrolling an additional 100 patients into
a trial at the Moffitt Center, and over the next six to nine months
we'll be finalizing the data. Our goal is to be able to go to the FDA
and show them how important genetic ancestry is. When we originally
looked at the data on a prospective basis of patient populations, we
couldn't make sense of it. That's part of the problem with gene data, no
matter what technology you are using. If you don't understand the
ancestry, or the genetic inheritance that goes along with that data,
it's very difficult puzzle to solve because hundreds and hundreds of
genes need to be analyzed. We're not claiming that we have the end-all-
and-be-all answer, but we certainly have what we think is a reasonable
tool for analyzing that very complex data
FEATURED North Bay Resources Acquires Mt. Vernon Gold Mine, Sierra County, California, with Assays up to 4.8 oz. Au per Ton • Jul 18, 2024 9:00 AM
VAYK Expects Revenue from First Airbnb Property Starting from August • VAYK • Jul 18, 2024 9:00 AM
Nightfood Holdings Signs Letter of Intent for All-Stock Acquisition of CarryOutSupplies.com • NGTF • Jul 17, 2024 1:00 PM
Kona Gold Beverages Reaches Out to Largest Debt Holder for Debt Purchase Negotiation • KGKG • Jul 17, 2024 9:00 AM
Avant Technologies Welcomes Back Former CEO with Eye Toward Future Growth and Expansion • AVAI • Jul 17, 2024 8:00 AM
HealthLynked Expands Telemedicine Nationwide • HLYK • Jul 17, 2024 8:00 AM